Eledon Pharmaceuticals (ELDN): CD40L Pathway, Tegoprubart, Transplant & ALS Pipeline — February 2026
Eledon Pharmaceuticals (Nasdaq: ELDN) is a clinical-stage biotech targeting the CD40L pathway with tegoprubart, an IgG1 anti-CD40L antibody. Phase 2 BESTOW kidn
By ObjectWire Editorial
Life Biosciences FDA Clearance: ER-100 Epigenetic Reprogramming Trial for Glaucoma & NAION — January 2026
The FDA cleared Life Biosciences
By ObjectWire Editorial
Bio-Hacking Hub: Human Enhancement, Longevity & Performance Optimization
Complete coverage of the bio-hacking movement — from Bryan Johnson
By ObjectWire Editorial
Bianca Dias and the BBL Crisis: How
On February 19, 2026, in São Paulo, Brazil
By ObjectWire Editorial
Beyond the Hype: How Japan
On February 2, 2026, Japan
By ObjectWire Editorial
Trump
Rare earth minerals are essential for EV batteries and wind turbines — but mining them from the ocean floor could destroy undiscovered ecosystems. Trump
By ObjectWire Editorial
Who Owns the Ocean Floor? The Legal Battle Over Deep-Sea Mining Rights
No single country owns the deep ocean floor — but that hasn
By ObjectWire Editorial
Why Cobalt Is the New Oil: The Battery Metal Crunch Reshaping Global Power
Cobalt is the essential ingredient in every EV battery — and nearly 70% of it comes from a single conflict-torn country. As demand explodes and ethics scrutiny
By ObjectWire Editorial